RY 173.64 -0.3672% SHOP 148.58 -0.6486% TD 82.36 -0.9263% ENB 64.21 -0.2641% BN 83.24 -1.0579% TRI 230.54 0.013% CNQ 46.58 3.4881% CP 109.8 1.4131% CNR 148.11 0.8031% BMO 143.82 0.3489% BNS 73.94 0.5029% CSU 4345.0 -1.0785% CM 90.555 -0.1158% MFC 44.31 0.113% ATD 76.82 0.0521% NGT 60.2 -0.1327% TRP 69.31 1.0939% SU 56.975 0.9658% WCN 255.98 -0.7868% L 181.13 -0.1268%
Last update at 2025-01-17T21:10:00Z
Strategic Collaborations Aid QGEN Stock Amid Competition
Fri 17 Jan 25, 03:37 PMGMAB vs. QGEN: Which Stock Is the Better Value Option?
Thu 16 Jan 25, 04:40 PMBeiGene (ONC) Moves 8.9% Higher: Will This Strength Last?
Wed 15 Jan 25, 01:57 PMQIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
Wed 15 Jan 25, 01:13 PMQIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
Sun 12 Jan 25, 06:05 PMWill Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
Thu 09 Jan 25, 05:10 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 512.60M | 625.83M | 154.93M | -77.77600M | 225.74M |
| Minority interest | - | - | - | - | 0.00000M |
| Net income | 423.21M | 512.60M | 73.64M | -41.45500M | 190.38M |
| Selling general administrative | 129.72M | 128.08M | 110.15M | 112.26M | 141.21M |
| Selling and marketing expenses | 474.22M | 456.39M | 434.16M | 391.91M | 392.28M |
| Gross profit | 1384.56M | 1450.82M | 1227.81M | 1005.26M | 1000.96M |
| Reconciled depreciation | 208.40M | 214.93M | 205.01M | 231.46M | 206.44M |
| Ebit | 531.46M | 630.08M | 554.90M | 336.22M | 293.03M |
| Ebitda | 824.12M | 923.00M | 764.87M | 567.68M | 499.47M |
| Depreciation and amortization | 292.66M | 292.92M | 209.97M | 231.46M | 206.44M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 531.46M | 630.08M | 554.90M | 336.22M | 266.58M |
| Other operating expenses | 1565.29M | 1593.81M | 1325.48M | 1212.75M | 1235.27M |
| Interest expense | 58.36M | 54.48M | 73.00M | 74.19M | 67.29M |
| Tax provision | 89.39M | 113.23M | 80.28M | -36.32100M | 35.36M |
| Interest income | 32.76M | 9.55M | 10.03M | 22.11M | 20.85M |
| Net interest income | -25.60000M | -44.92200M | -61.28500M | -52.07200M | -46.44200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 89.39M | 113.23M | 81.29M | -36.32100M | 35.36M |
| Total revenue | 2141.52M | 2251.66M | 1870.35M | 1526.42M | 1501.85M |
| Total operating expenses | 808.34M | 792.97M | 682.94M | 691.59M | 734.38M |
| Cost of revenue | 756.96M | 800.84M | 642.54M | 521.16M | 500.89M |
| Total other income expense net | -18.85900M | -4.25100M | -399.97400M | -413.99400M | 5.60M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 423.21M | 512.60M | 359.19M | -41.45500M | 190.38M |
| Net income applicable to common shares | 575.66M | 512.60M | 359.19M | -41.45500M | 190.38M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 6287.73M | 6146.95M | 5971.20M | 5235.62M | 5748.33M |
| Intangible assets | 544.80M | 627.44M | 883.60M | 632.43M | 475.04M |
| Earning assets | - | - | - | - | - |
| Other current assets | 293.98M | 354.64M | 182.30M | 105.46M | 109.16M |
| Total liab | 2821.12M | 3050.40M | 3488.15M | 2699.03M | 3113.36M |
| Total stockholder equity | 3466.61M | 3096.55M | 2483.05M | 2536.59M | 2634.97M |
| Deferred long term liab | 33.12M | 28.93M | 25.39M | - | - |
| Other current liab | 417.24M | 505.25M | 372.60M | 532.81M | 354.30M |
| Common stock | 2.70M | 2.70M | 2.70M | 2.70M | 2.70M |
| Capital stock | 2.70M | 2.70M | 2.70M | 2.70M | 2.70M |
| Retained earnings | 2160.17M | 1465.07M | 758.53M | 868.84M | 1068.98M |
| Other liab | 411.93M | 438.79M | 516.40M | 280.91M | 451.79M |
| Good will | 2352.57M | 2350.76M | 2389.11M | 2140.50M | 2108.54M |
| Other assets | 269.59M | 420.97M | 468.61M | 294.93M | 422.50M |
| Cash | 730.67M | 880.52M | 597.00M | 623.65M | 1159.08M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 974.52M | 1517.47M | 613.81M | 951.35M | 972.19M |
| Current deferred revenue | 69.00M | 63.37M | 57.07M | 48.52M | 45.36M |
| Net debt | 1130.78M | 1061.25M | 1429.74M | 1082.70M | 1015.13M |
| Short term debt | 389.55M | 847.63M | 65.99M | 285.24M | 503.12M |
| Short long term debt | 389.55M | 847.63M | 42.54M | 285.24M | 503.12M |
| Short long term debt total | 1861.45M | 1941.77M | 2026.74M | 1706.35M | 2174.21M |
| Other stockholder equity | 1707.83M | 1955.45M | 1961.41M | 1974.67M | 1563.64M |
| Property plant equipment | 586.56M | 638.18M | 661.89M | 512.55M | 511.66M |
| Total current assets | 2393.95M | 2109.60M | 1641.71M | 1570.25M | 2155.06M |
| Long term investments | 23.55M | - | 15.43M | 87.05M | 75.53M |
| Net tangible assets | 293.61M | 118.35M | -292.38600M | -236.34600M | 51.39M |
| Short term investments | 687.60M | 184.78M | 117.25M | 129.59M | 234.61M |
| Net receivables | 323.75M | 362.13M | 439.85M | 427.24M | 386.55M |
| Long term debt | 1471.90M | 1094.14M | 1880.21M | 1421.11M | 1671.09M |
| Inventory | 357.96M | 327.52M | 291.18M | 170.70M | 162.91M |
| Accounts payable | 98.73M | 101.22M | 118.15M | 84.77M | 69.42M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -404.09100M | -326.67000M | -239.60000M | -309.61900M | -310.64400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 2.70M | 2.70M | 2.70M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | -111.96600M | -178.90300M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 254.40M | 157.64M | 423.77M | 188.38M | 464.54M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3893.78M | 4037.35M | 4329.48M | 3665.37M | 3593.27M |
| Capital lease obligations | 22.22M | 22.05M | 23.45M | 18.74M | 0.06M |
| Long term debt total | - | - | - | 1421.11M | 1671.09M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -726.76300M | -40.73500M | -443.28100M | -222.27800M | -211.35600M |
| Change to liabilities | -1.75600M | -5.97500M | 8.44M | 9.25M | 6.99M |
| Total cashflows from investing activities | -735.58400M | -202.42600M | -443.28100M | -222.27800M | -211.35600M |
| Net borrowings | -135.39300M | -41.34500M | -35.55200M | -640.16300M | 493.57M |
| Total cash from financing activities | -125.80300M | -150.36600M | -74.32000M | -639.08000M | 360.41M |
| Change to operating activities | 68.12M | -130.01200M | 36.89M | 22.81M | -37.66000M |
| Net income | 423.21M | 512.60M | 73.64M | -41.45500M | 190.38M |
| Change in cash | -149.84700M | 282.53M | -31.22600M | -529.68900M | 501.37M |
| Begin period cash flow | 880.52M | 597.98M | 628.23M | 1159.08M | 657.71M |
| End period cash flow | 730.67M | 880.52M | 597.00M | 629.39M | 1159.08M |
| Total cash from operating activities | 715.26M | 639.00M | 492.27M | 330.84M | 359.50M |
| Issuance of capital stock | 0.12M | 7.92M | 7.66M | 2.08M | 4.41M |
| Depreciation | 208.40M | 214.93M | 209.97M | 231.46M | 206.44M |
| Other cashflows from investing activities | -9.77400M | 44.84M | -58.40800M | 22.70M | -18.52000M |
| Dividends paid | - | - | 622.20M | - | 567.28M |
| Change to inventory | -61.95000M | -81.80300M | -107.57300M | -30.02800M | -36.91800M |
| Change to account receivables | 15.45M | -7.40200M | -14.71100M | -39.57800M | -41.81300M |
| Sale purchase of stock | 0.00000M | -99.98700M | -63.99500M | -74.45000M | -104.68500M |
| Other cashflows from financing activities | 354.08M | -16.95300M | 1220.95M | -60.30500M | 1029.27M |
| Change to netincome | -95.02300M | 41.48M | -76.44700M | 144.40M | 22.30M |
| Capital expenditures | 149.34M | 206.53M | 304.24M | 274.88M | 150.76M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -31.88100M | -130.01200M | 16.80M | -44.32400M | -95.15900M |
| Stock based compensation | 49.51M | 38.39M | 40.94M | 65.89M | 40.11M |
| Other non cash items | 75.63M | 8.38M | 165.18M | 174.63M | 41.00M |
| Free cash flow | 565.93M | 432.47M | 188.03M | 55.96M | 208.73M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| QGEN Qiagen NV |
0.10 0.22% | 46.00 | 29.79 | 19.65 | 4.90 | 2.60 | 5.15 | 14.77 |
| TMO Thermo Fisher Scientific Inc |
-2.06 0.37% | 559.65 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-3.54 1.46% | 238.36 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| IDXX IDEXX Laboratories Inc |
-9.36 2.18% | 419.26 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
| IQV IQVIA Holdings Inc |
-0.3 0.15% | 197.36 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Hulsterweg 82, Venlo, Netherlands, 5912 PL
| Name | Title | Year Born |
|---|---|---|
| Mr. Thierry Bernard | CEO, MD & Member of Management Board | 1965 |
| Dr. Roland Sackers | CFO, MD & Member of Management Board | 1969 |
| Mr. Antonio Santos | Sr. VP & Head of Global Operations | NA |
| Mr. John Gilardi | VP of Corp. Communications & Investor Relations | NA |
| Ms. Stephany Foster | Sr. VP & Head of HR | 1978 |
| Dr. Thomas Schweins | Sr. VP of Life Science Bus. Area | NA |
| Dr. Thomas Theuringer | Sr. Director & Head of External Communications | NA |
| Mr. Jean-Pascal Viola | Sr. VP & Head of Molecular Diagnostics Bus. Area | NA |
| Dr. Jonathan G. Sheldon Ph.D. | Sr. VP of Qiagen Digital Insights Bus. Area | 1972 |
| Mr. Thomas Neidert | VP of Global Treasury | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...